Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs
Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more effi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/8/2214 |
| _version_ | 1797559636770947072 |
|---|---|
| author | Gonçalo Outeiro-Pinho Daniela Barros-Silva Margareta P. Correia Rui Henrique Carmen Jerónimo |
| author_facet | Gonçalo Outeiro-Pinho Daniela Barros-Silva Margareta P. Correia Rui Henrique Carmen Jerónimo |
| author_sort | Gonçalo Outeiro-Pinho |
| collection | DOAJ |
| description | Renal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more efficient patient management. Nonetheless, currently available tools provide limited information and novel strategies are needed. Over the years, a putative role of non-coding RNAs (ncRNAs) as disease biomarkers has gained relevance and is now one of the most prolific fields in biological sciences. Herein, we extensively sought the most significant reports on ncRNAs as potential RCTs’ diagnostic, prognostic, predictive, and monitoring biomarkers. We could conclude that ncRNAs, either alone or in combination with currently used clinical and pathological parameters, might represent key elements to improve patient management, potentiating the implementation of precision medicine. Nevertheless, most ncRNA biomarkers require large-scale validation studies, prior to clinical implementation. |
| first_indexed | 2024-03-10T17:48:09Z |
| format | Article |
| id | doaj.art-a6d63f1d9e8e451a976f8e26f486e97b |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T17:48:09Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-a6d63f1d9e8e451a976f8e26f486e97b2023-11-20T09:27:53ZengMDPI AGCancers2072-66942020-08-01128221410.3390/cancers12082214Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAsGonçalo Outeiro-Pinho0Daniela Barros-Silva1Margareta P. Correia2Rui Henrique3Carmen Jerónimo4Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalCancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, PortugalRenal cell tumors (RCT) remain as one of the most common and lethal urological tumors worldwide. Discrimination between (1) benign and malignant disease, (2) indolent and aggressive tumors, and (3) patient responsiveness to a specific therapy is of major clinical importance, allowing for a more efficient patient management. Nonetheless, currently available tools provide limited information and novel strategies are needed. Over the years, a putative role of non-coding RNAs (ncRNAs) as disease biomarkers has gained relevance and is now one of the most prolific fields in biological sciences. Herein, we extensively sought the most significant reports on ncRNAs as potential RCTs’ diagnostic, prognostic, predictive, and monitoring biomarkers. We could conclude that ncRNAs, either alone or in combination with currently used clinical and pathological parameters, might represent key elements to improve patient management, potentiating the implementation of precision medicine. Nevertheless, most ncRNA biomarkers require large-scale validation studies, prior to clinical implementation.https://www.mdpi.com/2072-6694/12/8/2214Renal cell tumorsrenal cell carcinomabiomarkersliquid biopsiesdiagnosisprognosis |
| spellingShingle | Gonçalo Outeiro-Pinho Daniela Barros-Silva Margareta P. Correia Rui Henrique Carmen Jerónimo Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs Cancers Renal cell tumors renal cell carcinoma biomarkers liquid biopsies diagnosis prognosis |
| title | Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs |
| title_full | Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs |
| title_fullStr | Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs |
| title_full_unstemmed | Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs |
| title_short | Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs |
| title_sort | renal cell tumors uncovering the biomarker potential of ncrnas |
| topic | Renal cell tumors renal cell carcinoma biomarkers liquid biopsies diagnosis prognosis |
| url | https://www.mdpi.com/2072-6694/12/8/2214 |
| work_keys_str_mv | AT goncaloouteiropinho renalcelltumorsuncoveringthebiomarkerpotentialofncrnas AT danielabarrossilva renalcelltumorsuncoveringthebiomarkerpotentialofncrnas AT margaretapcorreia renalcelltumorsuncoveringthebiomarkerpotentialofncrnas AT ruihenrique renalcelltumorsuncoveringthebiomarkerpotentialofncrnas AT carmenjeronimo renalcelltumorsuncoveringthebiomarkerpotentialofncrnas |